Related Experiment Video

Updated: Oct 5, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K

Trabectedin for recurrent WHO grade 2 or 3 meningiomas-Paving the road for new opportunities

Christopher A Alvarez-Breckenridge1, Daniel P Cahill2, Priscilla K Brastianos3

  • 1Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Neuro-Oncology
|January 31, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.4K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.6K

Related Experiment Videos

Last Updated: Oct 5, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.4K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

Articles linked to this work by shared authors, journal, and citation graph.

Neoadjuvant Treatment of BRAFV600E Papillary Craniopharyngiomas: A Case Series.

Operative neurosurgery (Hagerstown, Md.)·2026

Combination treatment with RAF/MEK inhibitor avutometinib and FAK inhibitor defactinib in preclinical models of meningioma.

Neuro-oncology advances·2026

Spinal laser interstitial thermal therapy for treatment of chordoma: single-center experience and literature review.

Journal of neuro-oncology·2026

Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma.

Science translational medicine·2026

Oxidized protein states define metastatic fitness in lung cancer.

bioRxiv : the preprint server for biology·2026

Applicability of RECIST1.1, MDACC and SPINO Tumor Response Criteria After Adjuvant Stereotactic Spinal Radiosurgery in Surgically Treated Spinal Metastases.

Medicina (Kaunas, Lithuania)·2026

Firmonertinib 160mg in EGFR-Mutated NSCLC with Brain Metastases After EGFR-TKI Resistance (iFORCE): Clinical Outcomes and Mechanistic Insights.

Neuro-oncology·2026

MRI-Based Machine Learning to Differentiate True Progression from Pseudoprogression in Glioblastoma: An Updated Systematic Review and Meta-Analysis.

Neuro-oncology·2026

Biomarker-guided treatment strategies for patients with gliomas in clinical practice.

Neuro-oncology·2026

Unilateral vs Bilateral Hippocampal Avoidance During WBRT With Memantine for Brain Metastases: A Randomized Single-Blind Phase 2 Clinical Trial.

Neuro-oncology·2026

Routing to the seizure in postoperative human glioma cortex: spatio-temporal uncoupling between slow and fast extracellular neuronal activities.

Neuro-oncology·2026

Prognostic Significance of Contrast Enhancement in Newly Diagnosed Grade 2 IDH-mutant Glioma.

Neuro-oncology·2026

Hybrid exosome-liposome nanovesicles as delivery platforms for therapeutic applications: merging the best of both worlds.

Theranostics·2026

A nanoengineered MSC therapeutic for synergistic therapy of lupus nephritis via cfDNA clearance and targeted immunomodulation.

Theranostics·2026

An inducible human LDLR transgenic mouse model for enhanced lentiviral gene delivery to murine immune cells.

Frontiers in immunology·2026

Transcranial ultrasound stimulation of the right globus pallidus interna in schizophrenia: A randomized, sham-controlled pilot study.

NPJ acoustics·2026

Case report: Clinical utility and limitations of high-frequency ultrasound for monitoring sonidegib response in nodular basal cell carcinoma: a three-case series.

Frontiers in oncology·2026

Mitochondrial dysfunction in Down syndrome B-cell acute lymphoblastic leukemia can be targeted using venetoclax.

Haematologica·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us